730 related articles for article (PubMed ID: 34471255)
1. Cellular host factors for SARS-CoV-2 infection.
Baggen J; Vanstreels E; Jansen S; Daelemans D
Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
[TBL] [Abstract][Full Text] [Related]
2. Host proviral and antiviral factors for SARS-CoV-2.
Lv L; Zhang L
Virus Genes; 2021 Dec; 57(6):475-488. PubMed ID: 34510331
[TBL] [Abstract][Full Text] [Related]
3. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
van de Leemput J; Han Z
Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
[TBL] [Abstract][Full Text] [Related]
4. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus biology and replication: implications for SARS-CoV-2.
V'kovski P; Kratzel A; Steiner S; Stalder H; Thiel V
Nat Rev Microbiol; 2021 Mar; 19(3):155-170. PubMed ID: 33116300
[TBL] [Abstract][Full Text] [Related]
6. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
[TBL] [Abstract][Full Text] [Related]
7. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.
Santopolo S; Riccio A; Santoro MG
Biochem Biophys Res Commun; 2021 Jan; 538():80-87. PubMed ID: 33303190
[TBL] [Abstract][Full Text] [Related]
8. Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics.
Terracciano R; Preianò M; Fregola A; Pelaia C; Montalcini T; Savino R
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430309
[TBL] [Abstract][Full Text] [Related]
9. An overview of potential therapeutic agents to treat COVID-19.
Dong X; Tian Z; Shen C; Zhao C
Biosci Trends; 2020 Nov; 14(5):318-327. PubMed ID: 33100290
[TBL] [Abstract][Full Text] [Related]
10. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
[TBL] [Abstract][Full Text] [Related]
11. Genome-scale CRISPR screens identify host factors that promote human coronavirus infection.
Grodzki M; Bluhm AP; Schaefer M; Tagmount A; Russo M; Sobh A; Rafiee R; Vulpe CD; Karst SM; Norris MH
Genome Med; 2022 Jan; 14(1):10. PubMed ID: 35086559
[TBL] [Abstract][Full Text] [Related]
12. Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.
Rajarshi K; Khan R; Singh MK; Ranjan T; Ray S; Ray S
Gene; 2021 Feb; 768():145313. PubMed ID: 33220345
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
14. Structural biology of SARS-CoV-2: open the door for novel therapies.
Yan W; Zheng Y; Zeng X; He B; Cheng W
Signal Transduct Target Ther; 2022 Jan; 7(1):26. PubMed ID: 35087058
[TBL] [Abstract][Full Text] [Related]
15. Effective inhibition of coronavirus replication by
Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
[No Abstract] [Full Text] [Related]
16. Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.
Wang R; Simoneau CR; Kulsuptrakul J; Bouhaddou M; Travisano KA; Hayashi JM; Carlson-Stevermer J; Zengel JR; Richards CM; Fozouni P; Oki J; Rodriguez L; Joehnk B; Walcott K; Holden K; Sil A; Carette JE; Krogan NJ; Ott M; Puschnik AS
Cell; 2021 Jan; 184(1):106-119.e14. PubMed ID: 33333024
[TBL] [Abstract][Full Text] [Related]
17. The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.
Wong NA; Saier MH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525632
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
19. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
20. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.
Meyer B; Chiaravalli J; Gellenoncourt S; Brownridge P; Bryne DP; Daly LA; Grauslys A; Walter M; Agou F; Chakrabarti LA; Craik CS; Eyers CE; Eyers PA; Gambin Y; Jones AR; Sierecki E; Verdin E; Vignuzzi M; Emmott E
Nat Commun; 2021 Sep; 12(1):5553. PubMed ID: 34548480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
